178 related articles for article (PubMed ID: 34965569)
21. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
22. Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.
Cueva JF; Antolín S; Calvo L; Fernández I; Ramos M; de Paz L; Mata JG; López R; Constenla M; Pérez E; González A; Pellón ML; Varela S; López T
Clin Transl Oncol; 2017 Sep; 19(9):1067-1078. PubMed ID: 28342058
[TBL] [Abstract][Full Text] [Related]
23. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
[TBL] [Abstract][Full Text] [Related]
24. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
26. Causal Phenotyping for Susceptibility to Cardiotoxicity from Antineoplastic Breast Cancer Medications.
Sun D; Simon GJ; Skube S; Blaes AH; Melton GB; Zhang R
AMIA Annu Symp Proc; 2017; 2017():1655-1664. PubMed ID: 29854236
[TBL] [Abstract][Full Text] [Related]
27. Identification of Clinical and Laboratory Variables Associated with Cardiotoxicity Events Due to Doxorubicin in Breast Cancer Patients: A 1-Year Follow-Up Study.
Simões R; Silva LM; de Oliveira AN; Alves MT; Pestana RMC; de Souza IDP; Oliveira HHM; Soares CE; Sabino AP; Gomes KB
Cardiovasc Toxicol; 2021 Feb; 21(2):106-114. PubMed ID: 32844368
[TBL] [Abstract][Full Text] [Related]
28. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
[TBL] [Abstract][Full Text] [Related]
29. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
30. Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy.
de Barros MVL; Macedo AVS; Sarvari SI; Faleiros MH; Felipe PT; Silva JLP; Edvardsen T
Arq Bras Cardiol; 2019 Jan; 112(1):50-56. PubMed ID: 30569947
[TBL] [Abstract][Full Text] [Related]
31. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
32. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
33. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
34. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.
Cao L; Cai G; Chang C; Yang ZZ; Feng Y; Yu XL; Ma JL; Wu J; Guo XM; Chen JY
Oncotarget; 2016 Jan; 7(1):1042-54. PubMed ID: 26460956
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of cardiac toxicity of systemic treatments in Moroccan patients followed for localized breast cancer: Prospective observational study of 549 cases.
Haffadi M; Tawfiq N; Dakir M; Boughafour M; Bouchbika Z; Benchakroun N; Jouhadi H; Sahraoui S; Benider A; Krikez I; Benmallek R; Habbal R
Gulf J Oncolog; 2021 Jan; 1(35):59-65. PubMed ID: 33716214
[TBL] [Abstract][Full Text] [Related]
36. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines.
Peddi P; Master SR; Dwary AD; Ravipati HP; Patel AH; Pasam A; Katikaneni PK; Shi R; Burton GV; Chu QD
Breast J; 2019 Jan; 25(1):62-68. PubMed ID: 30592128
[TBL] [Abstract][Full Text] [Related]
37. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
Cho H; Lee S; Sim SH; Park IH; Lee KS; Kwak MH; Kim HJ
Breast Cancer Res Treat; 2020 Jul; 182(2):333-343. PubMed ID: 32468335
[TBL] [Abstract][Full Text] [Related]
38. Role of Speckle Tracking Echocardiography in the Evaluation of Breast Cancer Patients Undergoing Chemotherapy: Review and Meta-analysis of the Literature.
Bergamini C; Dolci G; Truong S; Zanolla L; Benfari G; Fiorio E; Rossi A; Ribichini FL
Cardiovasc Toxicol; 2019 Dec; 19(6):485-492. PubMed ID: 31049776
[TBL] [Abstract][Full Text] [Related]
39. Anthracycline Chemotherapy-Induced Cardiotoxicity in Breast Cancer Survivors: A Systematic Review.
Lin KJ; Lengacher CA
Oncol Nurs Forum; 2019 Sep; 46(5):E145-E158. PubMed ID: 31424455
[TBL] [Abstract][Full Text] [Related]
40. Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study.
Thavendiranathan P; Abdel-Qadir H; Fischer HD; Camacho X; Amir E; Austin PC; Lee DS
J Clin Oncol; 2016 Jul; 34(19):2239-46. PubMed ID: 27091709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
